Piper Sandler Reiterates Overweight on NewAmsterdam Pharma, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has reiterated its Overweight rating on NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a price target of $37.
September 23, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reiterated its Overweight rating on NewAmsterdam Pharma, maintaining a $37 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and maintenance of a $37 price target by Piper Sandler suggests continued confidence in NewAmsterdam Pharma's growth prospects, likely leading to positive investor sentiment and potential short-term stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100